VBLT News
Archived Headlines
- Vascular Biogenics prices IPO at $12, below the range 07/31/14
- 22 US IPOs planned for the week of Jul 28 07/28/14
- Gene therapy biotech Vascular Biogenics sets terms for $76 million IPO 07/16/14
- Gene therapy biotech Vascular Biogenics files for a $75 million IPO to develop its cancer treatment 06/06/14
US IPO Pricing Recap: 11 IPOs trade poorly but investors can't get enough American Addiction
11 IPOs priced during the week of September 29, but only 3 had any meaningful gains, including two tech deals and American Addiction Centers, a network of substance abuse treatment centers. The group raised $2.4 billion; 25% less than expected after frac sand...read more
Vascular Biogenics prices previously canceled IPO at $6
Vascular Biogenics, which is developing gene therapies for cancer and small molecules for inflammation, raised $40 million by offering 6.7 million shares at $6, below the range of $13 to $15. Insiders planned to purchase 4.0 million shares (60% of the deal)....read more
US IPO Pricing Recap: 15 IPOs in the most active week since 2007; 66% ended at or below IPO price
15 companies had initial public offerings and raised $6.4 billion this week, making it the most active week in the IPO market since 2007. Including deals that priced yesterday and began trading today, July saw 34 IPOs, a post-tech bubble record....read more
IPO market brought down by biotech wreck and market sell off
Last night 12 IPOs were expected to price, but only 8 did. Two deals were postponed: extended release biotech Mapi-Pharma (MAPI) and cardiovascular diagnostic firm Lantheus (LNTH). Two deals were delayed a day: osteoporosis patch biotech Zosano...read more